T-COVRIMUNE Trademark

Trademark Overview

On Monday, June 14, 2021, a trademark application was filed for T-COVRIMUNE with the United States Patent and Trademark Office. The USPTO has given the T-COVRIMUNE trademark a serial number of 90772191. The federal status of this trademark filing is FOURTH EXTENSION - GRANTED as of Wednesday, May 8, 2024. This trademark is owned by ImmunityBio, Inc.. The T-COVRIMUNE trademark is filed in the Pharmaceutical Products category with the following description:

Medicinal preparations; biological preparations; pharmaceutical preparations; vaccines; immune boosters, namely, medicinal, biological and pharmaceutical preparations in the nature of vaccines; all of the aforementioned for use in the treatment and/or prevention of cancer and infectious diseases including coronavirus
t-covrimune

General Information

Serial Number90772191
Word MarkT-COVRIMUNE
Filing DateMonday, June 14, 2021
Status733 - FOURTH EXTENSION - GRANTED
Status DateWednesday, May 8, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 22, 2022

Trademark Statements

Goods and ServicesMedicinal preparations; biological preparations; pharmaceutical preparations; vaccines; immune boosters, namely, medicinal, biological and pharmaceutical preparations in the nature of vaccines; all of the aforementioned for use in the treatment and/or prevention of cancer and infectious diseases including coronavirus

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, February 11, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameImmunityBio, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92121
Party NameImmunityBio, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92121

Trademark Events

Event DateEvent Description
Thursday, June 17, 2021NEW APPLICATION ENTERED
Wednesday, September 1, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, January 19, 2022ASSIGNED TO EXAMINER
Thursday, January 27, 2022EXAMINER'S AMENDMENT ENTERED
Thursday, January 27, 2022EXAMINERS AMENDMENT -WRITTEN
Thursday, January 27, 2022EXAMINERS AMENDMENT E-MAILED
Thursday, January 27, 2022NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Friday, February 11, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 2, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, March 22, 2022PUBLISHED FOR OPPOSITION
Thursday, October 20, 2022SOU TEAS EXTENSION RECEIVED
Thursday, October 20, 2022SOU EXTENSION 1 FILED
Thursday, October 20, 2022SOU EXTENSION 1 GRANTED
Wednesday, February 16, 2022ASSIGNED TO LIE
Tuesday, March 22, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 17, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Saturday, October 22, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, April 5, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, April 5, 2023SOU EXTENSION 2 FILED
Wednesday, April 5, 2023SOU EXTENSION 2 GRANTED
Friday, April 7, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, October 25, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, May 8, 2024SOU EXTENSION 4 GRANTED
Wednesday, May 8, 2024SOU EXTENSION 4 FILED
Wednesday, May 8, 2024SOU TEAS EXTENSION RECEIVED
Thursday, May 9, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, October 23, 2023SOU EXTENSION 3 GRANTED
Monday, October 23, 2023SOU TEAS EXTENSION RECEIVED
Monday, October 23, 2023SOU EXTENSION 3 FILED

Related Keywords

covrimune preparations vaccines medicinal pharmaceutical biological infectious cancer coronavirus prevention including